Information Library

Results for: Cost control/reduction - Late Phase

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Population PK/PD - Modeling and Simulation Optimization Tools

    Brochure — February 11, 2011
    Population pharmacokinetic/ pharmacodynamic (PK/PD) modeling and simulation, available from Quintiles, is now endorsed by the FDA as often being instrumental in drug approval and labeling.

  • New FDA Guidance on Antidiabetic Therapies

    White Paper — December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

  • QUINTILES INCREASES CAPACITY TO SUPPORT EUROPEAN CLINICAL TRIALS

    Press Release — September 24, 2009 - Quintiles Transnational Corp. announced the opening of an expanded regional facility near Edinburgh, Scotland; space for Quintiles Clinical Development Services, including Project Management, Regulatory Affairs and Data Management.

  • Early phase strategies

    Hear from the Experts — June 15, 2009
    Web cast about Early Phase Strategies.

  • Risk Assessment & Strategy

    Brochure — April 16, 2009
    Quintiles benefit risk analysis can help you anticipate potential regulatory concerns and highlight the benefit side of your drug’s benefit risk profile.

  • How to Navigate the New CDISC Standard

    Brochure — March 25, 2009
    Quintiles – a CDISC Registered Solutions Provider – helps you get every detail right.

  • Antibiotic Safety Assessment

    Case Study — March 25, 2009
    A major pharmaceutical company presented Quintiles with a pressing challenge – to collect extensive amounts of Phase IV data in compressed time windows because the treatment conditions were subject to seasonal variants.

Page 1 of 1 (7 results)

Subscribe to Email Based on Your Interests

Set preferences